Back to Results

MGAH22 in Breast Cancer

Title Breast Cancer - Determining Effect of MGAH22 in Breast Cancer Patients
Therapeutic Area Breast Cancer
Principal Investigator John Erban, MD
Min Age 18 Years
Gender Female
Contact Madeline Arthur


To determine if MGAH22 has sufficient activity in the population of breast cancer participants whose tumors exhibit 2+ HER2 oncoprotein expression and lacks HER2 gene amplification.

Study Details

Inclusion Criteria

  • Participants must have invasive carcinoma of the breast
  • Adequate organ reserve including cardiovascular, pulmonary, renal, hepatic functioning sufficient to undergo therapy.

Exclusion Criteria

  • Participants who have had major surgery or trauma within four weeks before enrollment
  • History within three months of enrollment of deep vein thrombosis, pulmonary embolism, or stroke.
  • Any serious underlying medical condition that would impair the ability to receive or tolerate the planned treatment

Study Requirements

Screening tests must be done within 4 weeks before participants receive the first dose of MGAH22. The tests will check their medical history and overall health and the tests will measure their disease with a CT scan.The test drug MGAH22 will be given once a week for 3 weeks on Days 1, 8, and 15 of each cycle. The study drug will be given through a thin plastic tube that is placed into the arm vein.Participants will have blood draws, CT scans and other exams as per protocol.